Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants

Journal of Thrombosis and Thrombolysis

Volumn 41, Issue 2, 2016, Pages 248-252

  Ansell, Jack E ^a,b  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b NONE   (United States)

Author keywords

Andexanet alfa; Anticoagulants; Antidotes; Ciraparantag; Direct oral anticoagulants; Idarucizumab; PER977; Reversal agents

Indexed keywords

ANDEXANET ALFA; ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CIRAPARANTAG; DABIGATRAN; ENOXAPARIN; IDARUCIZUMAB; PROTHROMBIN COMPLEX; ANTIDOTE; BLOOD CLOTTING FACTOR 10A; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ARTICLE; BLEEDING; BLEEDING RISK; BLEEDING TENDENCY; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; DRUG EFFICACY; DRUG SPECIFICITY; ERYTHROCYTE TRANSFUSION; HEMOSTASIS; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK; RISK ASSESSMENT; THROMBIN TIME; UNSPECIFIED SIDE EFFECT; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIDOTES; FACTOR XA; FACTOR XA INHIBITORS; HUMANS; RECOMBINANT PROTEINS;

EID: 84956880699     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-015-1288-1     Document Type: Article

References (30)

1. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1964129-33f4-4e4e-86e3-8e6a4e65bd83. Accessed 8 Mar 15
2. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) The pharmacology and management of the vitamin K antagonists: ACCP evidence-based clinical practice guidelines. Chest 133:160S–198S
3. Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Antithrombotic therapy and prevention of thrombosis: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e24S–e43S
4. Weitz JI, Eikelboom JW, Samama MM (2012) New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis: American college of chest physicians evidence-based clinical practice guidelines. Chest J 141(2_suppl):e120S–e151S
5. Roldan V, Marin F (2012) Pro: antidote for new anticoagulants—specific target of inhibition requires a specific target for neutralisation. Thromb Haemost 108:621–622
6. Eerenberg ES, Levi M, Buller HR (2012) Contra: antidotes for novel anticoagulants—do we really need them. Thromb Haemost 108:623–624
7. Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S (2013) Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 128:2325–2332
8. Piccini JP, Garg J, Patel MR, Lokhnygina Y, Goodman SG, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Mahaffey KW, Singer DE, Califf RM, Fox KAA (2014) Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J 35:1873–1880
9. Costin J, Ansell J, Laulicht B, Bakhru S, Steiner S (2014) Reversal agents in development for the new oral anticoagulants. Postgrad Med 126:19–24
10. Miller MP, Trujillo TC, Nordenholz KE (2014) Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants. Am J Emerg Med 32:375–382
11. Jackson LR, Becker RC (2014) Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. J Thromb Thrombolysis 37:380–391
12. Siegal DM (2015) Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis 39:395–402
13. Dickneite G, Hoffman M (2014) Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost 111:189–198
14. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:1573–1579
15. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. Thromb Haemost 108:217–224
16. Zahir H, Brown KS, Vandell A, Desai M, Maa JF, Dishy V, Lomeli B, Feussner A, Feng W, He L, Grosso MA, Lanz HJ, Antman EM (2014) Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 131:82–90
17. Kaatz S, Kouides PA, Garcia DA, Spyropoulos AC, Crowther M, Douketis JD, Chan AKC, James A, Moll S, Ortel TL, van Cott EM, Ansell J (2012) Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 87:S141–S145
18. Miesbach W, Seifried E (2012) New direct oral anticoagulants-current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 108:625–632
19. Schiele F, van Ryn J, Canada K, Newsome C, Sepuveda E, Park J, Nar J, Litzenburger T (2013) A specific antidote for dabigatran: functional and structural characterization. Blood 121:3554–3562
20. Glund S, Stangier J, Schmohl M, De Smet M, Gansser D, Lang B, Moschetti V, Ramael S, Reilly PA (2013) A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Circulation 128:A17765
21. Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kapmhusien PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511–520
22. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19:446–451
23. Gold AM, Crowther M, Levy G, Lu G, Leeds J, Barron L, Conley P, Castillo J, Curnutte J, Connolly S (2015) ANNEXA-R: a phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of rivaroxaban-induced anticoagulation in older subject by andexanet alfa, a universal antidote for factor Xa inhibitors. J Am Coll Cardiol 65:abst 23
24. Crowther M, Levy GG, Lu G, Leeds J, Barron L, Conley PB, Castillo J, Curnutte JT, Connolly S (2014) ANNEXA-A: a phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of apixaban-induced anticoagulation in older subjects by andexanet alfa, a universal antidote for factor Xa inhibitors. Circulation 130:2116
25. Crowther M, Gold A, Lu G, Leeds J, Wiens B, Mathur V, Castillo J, Conley P, Connolly S, Curnutte J (2015) ANNEXA-A part 2: a phase 3 randomized, double-blind, placebo-controlled trial demonstrating sustained reversal of apixaban-induced anticoagulation in older subjects by andexanet alfa, a universal antidote for factor Xa inhibitors. J Thromb Hemost 13(suppl. 2):84–85
26. Laulicht B, Bakhru S, Jiang X, Chen L, Pan D, Grosso M, Morishima Y, Brown K, Masumoto H, Costin J, Steiner S (2013) Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. Presented at the 24th congress of the international society on thrombosis and haemostasis, Amsterdam, June29–July 4, 2013. Abstract (http://www.eventure-online.com/eventure/publicAbstractView.do?id=226718&congressId=6839)
27. Bakhru S, Laulicht B, Jiang X, Chen I, Pan D, Grosso M, Morishima Y, Brown K, Masumoto H, Costin J, Steiner S (2013) PER977: a synthetic small molecule which reverses over-dosage and bleeding by the new oral anticoagulants. Circulation 128:A18809
28. Bakhru S, Laulicht B, Jiang X, Chen L, Grosso M, Morishima Y, Brown K, Mercuri M, Masumoto H, Costin J, Steiner S (2014) Reversal of anticoagulant-induced bleeding in external and internal bleeding models by PER977, a small molecule anticoagulant antidote. Circulation 130:A19361
29. Ansell JE, Bakhru S, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ (2014) Use of PER977 to reverse the anticoagulant effect of edoxaban. N Eng J Med 339:2141–2142
30. Ansell J (2015) Is there a need for an alternative in the era of novel anticoagulants? Exp Rev Cardiovasc Ther. doi:10.1586/14779072.2015.1069707